---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002636"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T01:59:04.592082+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# RxSight Q4 rev ~$28.6M (+78% YoY); FY2023 rev ~$89.1M (+82%); guides FY2024 rev $128-135M

## Summary
- Q4 2023 rev ~$28.6M (+78% YoY) driven by 77 LDD placements and 18,071 LALs sold.
- FY2023 rev ~$89.1M (+82% YoY); 666 LDD installed base; 54,873 LALs sold.
- Cash and investments ~$127.2M as of Dec 31, 2023.
- FY2024 revenue guidance of $128-135M (+44-52% YoY); gross margin 65-67%.
- Expects 2024 operating expenses $125-128M; non-cash expenses $22-25M.

## SEC filing metadata
- accession: 0000950170-24-002636
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/rxst-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002636
- JSON: https://secwatch.observer/filing/0000950170-24-002636.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002636.txt

## Key facts
- Earnings Releases
  RxSight, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.6 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: approximately $28.6 million
  - Result: preliminary results
  source text: Preliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm
- Earnings Releases
  RxSight, Inc. reported the fiscal year ended December 31, 2023 results: revenue approximately $89.1 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: approximately $89.1 million
  - Result: preliminary results
  source text: Preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm
- Earnings Releases
  RxSight, Inc. reported the fiscal year ending December 31, 2024 results: revenue $128.0 million to $135.0 million. Guidance initiated.
  - Period: the fiscal year ending December 31, 2024
  - Revenue: $128.0 million to $135.0 million
  - Guidance: initiated
  - Result: guidance update
  source text: RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.